The Future of Presbyopia Drops: Emerging Therapies and Clinical Insights

Overview

Since the FDA approval of Vuity in 2021, the presbyopia eye drop category has expanded with new agents like Qlosi gaining approval and others in late-stage development. These drops improve near vision by pupil constriction with varying mechanisms and safety profiles, offering promising non-surgical options for presbyopia management.

Background

Presbyopia, an age-related decline in near vision, traditionally requires corrective lenses or surgery. The approval of Vuity (pilocarpine hydrochloride 1.25%) introduced the first pharmacologic treatment, stimulating iris sphincter contraction to improve near and intermediate vision. Subsequent agents such as Qlosi and novel formulations like LNZ100 and Brimochol PF are advancing through clinical trials, aiming to enhance efficacy, duration, and tolerability. These developments reflect a growing pipeline targeting different mechanisms to address presbyopia in diverse patient populations.

Data Highlights

Key Findings

• Vuity, the first FDA-approved presbyopia drop, improves near vision within 15 minutes lasting 6-8 hours, with a favorable safety profile but limited to patients under 55 with early presbyopia.
• Qlosi, approved in 2023 but not yet marketed, offers similar efficacy at a lower pilocarpine dose and uses preservative-free single-use vials to reduce ocular surface toxicity.
• LNZ100 shows promise as a pupil-selective miotic that avoids myopic shift, with prolonged efficacy up to 10 hours and NDA submission accepted by FDA.
• Brimochol PF combines carbachol and brimonidine to enhance near vision while potentially reducing miotic-related side effects like headache, targeting patients over 55.
• Ryzumvi, originally approved for mydriasis reversal, is under phase 3 investigation for presbyopia treatment by selectively reducing pupil size without affecting accommodation.
• Side effects across agents commonly include headaches, blurred vision, and eye irritation; rare but serious risks like retinal detachment have been reported with pilocarpine drops.

Clinical Implications

Presbyopia eye drops represent a non-invasive alternative to glasses or surgery, particularly beneficial for early presbyopes with minimal refractive error. Clinicians should consider patient age, presbyopia severity, and ocular history when selecting therapy, monitoring for side effects such as accommodative spasm and retinal complications. Emerging agents with improved tolerability and longer duration may expand treatment options for older patients and those with advanced presbyopia.

Conclusion

The presbyopia drop landscape is rapidly evolving, with multiple FDA-approved and investigational agents offering tailored mechanisms to improve near vision safely and effectively. These pharmacologic therapies have the potential to transform presbyopia management by providing convenient, reversible, and preservative-free options.

References

1. AbbVie News Release 2021 -- FDA Approves Vuity for Presbyopia
2. Lievens et al. -- Pilocarpine HCl 1.25% for Presbyopia Treatment
3. FDA 2023 -- Approval of Qlosi for Presbyopia
4. LENZ Therapeutics 2024 -- LNZ100 Phase 3 CLARITY Trial Results
5. Tenpoint Therapeutics 2024 -- Brimochol PF Phase 3 Trials
6. Opus Genetics 2023 -- Ryzumvi FDA Approval and Presbyopia Trials